Tregzi: how was the first human dose set?

“This omission is acceptable, as the applicant provided safety data from a Phase 1/2 clinical study with a similar clinical product to support initiation of the Phase 1b study”

“Histopathological examination revealed dose-dependent T cell infiltration in hepatic periportal regions and parenchyma, thickening of intestinal lamina propria, and atrophy of subcutaneous fat and hair follicles”